Bony metastases: assessing response to therapy with whole-body diffusion MRI
نویسندگان
چکیده
منابع مشابه
Bony metastases: assessing response to therapy with whole-body diffusion MRI
There are no universally accepted methods for assessing tumour response in skeletal sites with metastatic disease; response is assessed by a combination of imaging tests, serum and urine biochemical markers and symptoms assessments. Whole-body diffusion magnetic resonance imaging excels at bone marrow assessments at diagnosis and for therapy evaluations. It can potentially address unmet clinica...
متن کاملTherapy monitoring of skeletal metastases with whole-body diffusion MRI.
Current methods of assessing tumor response at skeletal sites with metastatic disease use a combination of imaging tests, serum and urine biochemical markers, and symptoms assessment. These methods do not always enable the positive assessment of therapeutic benefit to be made but instead provide an evaluation of progression, which then guides therapy decisions in the clinic. Functional imaging ...
متن کاملAssessing extracranial tumors using diffusion-weighted whole-body MRI.
Diffusion-weighted magnetic resonance imaging (DWI) provides qualitative and quantitative information about the random motion of water molecules in biological tissues and is able to give functional insight into tissue architecture and pathological changes on a cellular level. This technique has the major advantages of not requiring the administration of contrast agents and not exposing the pati...
متن کاملWhole-body MRI and diffusion MRI
Metastatic bone disease is a common manifestation of advanced cancers with a very high prevalence in breast, prostate and lung cancers. In order to effectively manage patients with metastatic bony disease it is essential to have consistent, reproducible and validated methods for detecting and assessing the response to therapy. In response assessments, confident categorization of response is nee...
متن کاملTherapy response with diffusion MRI: an update
The efficiency of an oncological treatment regimen is often assessed by morphological criteria such as tumour size evaluated by cross-sectional imaging, or by laboratory measurements of plasma biomarkers. Because these types of measures typically allow for assessment of treatment response several weeks or even months after the start of therapy, earlier response assessment that provides insight ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer Imaging
سال: 2011
ISSN: 1470-7330
DOI: 10.1102/1470-7330.2011.9034